Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus

References

• Nikpour M., Urowitz M. B., Gladman D. D. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 329–54
   PubMed Web of Science ®Google Scholar
• Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16: 847–58
   PubMed Web of Science ®Google Scholar
• Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., , European Working Party on Systemic Lupus Erythematosus, et al. Morbidity and mortality in systemic lupus erythematosus during a 10‐year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299–308
   PubMed Web of Science ®Google Scholar
• Mok C. C., Mak A., Chu W. P., To C. H., Wong S. N. Long term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine (Baltimore) 2005; 84: 218–24
   PubMed Web of Science ®Google Scholar
• Urowitz M. B., Bookman A. A., Koehler B. E., Gordon D. A., Smythe H. A., Ogryzlo M. A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221–5
   PubMed Web of Science ®Google Scholar
• Bjornadal L., Yin L., Granath F., Klareskog L., Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964–95. J Rheumatol 2004; 31: 713–19
   PubMed Web of Science ®Google Scholar
• Meroni P. L., Borghi M. O., Raschi E., Ventura D., Sarzi Puttini P. C., Atzeni F., et al. Inflammatory response and the endothelium. Thromb Res 2004; 114((5–6))329–34
   PubMed Web of Science ®Google Scholar
• Constans J., Dupuy R., Blann A. D., Resplandy F., Seigneur M., Renard M., et al. Anti‐endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 2003; 30: 1963–6
   PubMed Web of Science ®Google Scholar
• Somers E. C., Marder W., Kaplan M. J., Brook R. D., McCune W. J. Plasminogen activator inhibitor‐1 is associated with impaired endothelial function in women with systemic lupus erythematosus. Ann N Y Acad Sci 2005; 1051: 271–80
   PubMed Web of Science ®Google Scholar
• Celermajer D. S., Sorensen K. E., Bull C., Robinson J., Deanfield J. E. Endothelium‐dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468–74
   PubMed Web of Science ®Google Scholar
• Neunteufl T., Katzenschlager R., Hassan A., Klaar U., Schwarzacher S., Glogar D., et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111–18
   PubMed Web of Science ®Google Scholar
• Asanuma Y., Oeser A., Shintani A. K., Turner E., Olsen N., Fazio S., et al. Premature coronary‐artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407–15
   PubMed Web of Science ®Google Scholar
• Manger K., Kusus M., Forster C., Ropers D., Daniel W. G., Kalden J. R., et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003; 62: 846–50
   PubMed Web of Science ®Google Scholar
• Bruce I. N., Gladman D. D., Ibanez D., Urowitz M. B. Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. J Rheumatol 2003; 30: 288–91
   PubMed Web of Science ®Google Scholar
• Sella E. M., Sato E. I., Leite W. A., Oliveira Filho J. A., Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1066–70
   PubMed Web of Science ®Google Scholar
• Roman M. J., Shanker B. A., Davis A., Lockshin M. D., Sammaritano L., Simantov R. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–406
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Jensen‐Urstad K., Heimburger M., Silveira A., Hamsten A., de Faire U., et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–93
   PubMed Web of Science ®Google Scholar
• Wolak T., Todosoui E., Szendro G., Bolotin A., Jonathan B. S., Flusser D., et al. Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J Rheumatol 2004; 31: 909–14
   PubMed Web of Science ®Google Scholar
• Doria A., Shoenfeld Y., Wu R., Gambari P. F., Puato M., Ghirardello A., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071–7
   PubMed Web of Science ®Google Scholar
• Selzer F., Sutton‐Tyrrell K., Fitzgerald S. G., Pratt J. E., Tracy R. P., Kuller L. H., et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151–9
   PubMed Web of Science ®Google Scholar
• Kron J., Hamper U. M., Petri M. Prevalence of cerebral microemboli in systemic lupus erythematosus: transcranial Doppler. J Rheumatol 2001; 28: 2222–5
   PubMed Web of Science ®Google Scholar
• Kumral E., Evyapan D., Keser G., Kabasakal Y., Oksel F., Aksu K., et al. Detection of microembolic signals in patients with neuropsychiatric lupus erythematosus. Eur Neurol 2002; 47: 131–5
   PubMed Web of Science ®Google Scholar
• Molad Y., Levin‐Iaina N., Vaturi M., Sulkes J., Sagie A., Molad Y., et al. Heart valve calcification in young patients with systemic lupus erythematosus: A window to premature atherosclerotic vascular morbidity and a risk factor for all‐cause mortality., doi: 10.1016/j.atherosclerosis.2005.06.021
   Google Scholar
• Adler Y., Fisman E. Z., Shemesh J., Tanne D., Hovav B., Motro M., et al. Usefulness of helical computed tomography in detection of mitral annular calcification as a marker of coronary artery disease. Int J Cardiol 2005; 101: 371–6
   PubMed Web of Science ®Google Scholar
• Petri M., Perez‐Gutthann S., Spence D., Hochberg M. C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513–19
   PubMed Web of Science ®Google Scholar
• Gladman D. D., Urowitz M. B. Morbidity in systemic lupus erythematosus. J Rheumatol 1987; 14((Suppl 13))223–6
   Google Scholar
• Manzi S., Meilahn E. N., Rairie J. E., Conte C. G., Medsger T. A Jr., Jansen‐McWilliams L., et al. Age‐specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–15
   PubMed Web of Science ®Google Scholar
• Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141–50
   PubMed Web of Science ®Google Scholar
• Bruce I. N., Urowitz M. B., Gladman D. D., Hallett D. C. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137–43
   PubMed Web of Science ®Google Scholar
• Esdaile J. M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–7
   PubMed Web of Science ®Google Scholar
• Ward M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338–46
   PubMed Web of Science ®Google Scholar
• Brey R. L., Holliday S. L., Saklad A. R., Navarrete M. G., Hermosillo‐Romo D., Stallworth C. L., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214–20
   PubMed Web of Science ®Google Scholar
• Manzi S., Selzer F., Sutton‐Tyrrell K., Fitzgerald S. G., Rairie J. E., Tracy R. P., et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51–60
   PubMed Web of Science ®Google Scholar
• Mok C. C., Lau C. S., Wong R. W. S. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766–71
   PubMed Web of Science ®Google Scholar
• Sanna G., Bertolaccini M. L., Cuadrado M. J., Laing H., Khamashta M. A., Mathieu A., et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985–92
   PubMed Web of Science ®Google Scholar
• Hanly J. G., McCurdy G., Fougere L., Douglas J. A., Thompson K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 2004; 31: 2156–62
   PubMed Web of Science ®Google Scholar
• Mok C. C., Tang S. S. K., To C. H., Petri M. A. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774–82
   PubMed Web of Science ®Google Scholar
• McDonald J., Stewart J., Urowitz M. B., Gladman D. D. Peripheral vascular disease in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 56–60
   PubMed Web of Science ®Google Scholar
• Hsu H. B., Sun S. S., Chen J. J., Tsai J. J., Kao C. H., ChangLai S. P. Usefulness of thallium‐201 muscle scan to investigate perfusion reserve in the lower limbs of patients with systemic lupus erythematosus. Rheumatol Int 2004; 24: 291–3
   PubMed Web of Science ®Google Scholar
• Lin C. C., Ding H. J., Chen Y. W., Wang J. J., Ho S. T., Kao A. High prevalence of asymptomatically poor muscle perfusion of lower extremities measured in systemic lupus erythematosus patients with abnormal myocardial perfusion. Rheumatol Int 2004; 24: 227–9
   PubMed Web of Science ®Google Scholar
• Toloza S. M., Uribe A. G., McGwin G Jr., Alarcon G. S., Fessler B. J., Bastian H. M., , LUMINA Study Group, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947–57
   PubMed Web of Science ®Google Scholar
• Rahman P., Aguero S., Gladman D. D., Hallett D., Urowitz M. B. Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000; 9: 672–75
   PubMed Web of Science ®Google Scholar
• Bruce I. N., Urowitz M. B., Gladman D. D., Ibanez D., Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159–67
   PubMed Web of Science ®Google Scholar
• Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res 2004; 114: 593–5
   PubMed Web of Science ®Google Scholar
• von Scheven E., Glidden D. V., Elder M. E. Anti‐beta2‐glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2002; 47: 414–20
   PubMed Web of Science ®Google Scholar
• Matsuura E., Kobayashi K., Koike T., Shoenfeld Y. Autoantibody‐mediated atherosclerosis. Autoimmun Rev 2002; 1: 348–53
   PubMedGoogle Scholar
• Matsuura E., Kobayashia K., Koikeb T., Shoenfeld Y., Khamashta M. A., Hughes G. R. Atherogenic autoantigen: oxidized LDL complexes with beta2‐glycoprotein I. Immunobiology 2003; 207: 17–22
   PubMed Web of Science ®Google Scholar
• Frostegard J., Svenungsson E., Wu R., Gunnarsson I., Lundberg I. E., Klareskog L., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192–200
   PubMed Web of Science ®Google Scholar
• Inoue T., Uchida T., Kamishirado H., Takayanagi K., Hayashi T., Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37: 775–9
   PubMed Web of Science ®Google Scholar
• Salonen J. T., Yla‐Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883–7
   PubMed Web of Science ®Google Scholar
• Shaw P. X., Horkko S., Tsimikas S., Chang M. K., Palinski W., Silverman G. J., et al. Human‐derived anti‐oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001; 21: 1333–9
   PubMed Web of Science ®Google Scholar
• Hayem G., Nicaise‐Roland P., Palazzo E., de Bandt M., Tubach F., Weber M., et al. Anti‐oxidized low‐density‐lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 2001; 10: 346–51
   PubMed Web of Science ®Google Scholar
• Horkko S., Miller E., Dudl E., Reaven P., Curtiss L. K., Zvaifler N. J., et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815–25
   PubMed Web of Science ®Google Scholar
• Horkko S., Olee T., Mo L., Branch D. W., Woods V. L Jr., Palinski W., et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)‐glycoprotein 1 and oxidized low‐density lipoprotein. Circulation 2001; 103: 941–6
   PubMed Web of Science ®Google Scholar
• Vaarala O., Alfthan G., Jauhiainen M., Leirisalo‐Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low‐density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923–5
   PubMed Web of Science ®Google Scholar
• Pierangeli S. S., Colden‐Stanfield M., Liu X., Barker J. H., Anderson G. L., Harris E. N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99: 1997–2002
   PubMed Web of Science ®Google Scholar
• Cederholm A., Svenungsson E., Jensen‐Urstad K., Trollmo C., Ulfgren A. K., Swedenborg J., et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005; 25: 198–203
   PubMed Web of Science ®Google Scholar
• Petri M., Roubenoff R., Dallal G. E., Nadeau M. R., Selhub J., Rosenberg I. H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120–4
   PubMed Web of Science ®Google Scholar
• Ibanez D., Gladman D. D., Urowitz M. B. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index‐2K is a predictor of outcome in SLE. J Rheumatol 2005; 32: 824–7
   PubMed Web of Science ®Google Scholar
• Sarnak M. J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41((5 Suppl))11–17
   PubMedGoogle Scholar
• Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–69
   PubMed Web of Science ®Google Scholar
• Fernandez M., Calvo‐Alen J., Alarcon G. S., Roseman J. M., Bastian H. M., Fessler B. J., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXI: Disease activity, damage accrual, and vascular events in pre‐ and postmenopausal women. Arthritis Rheum 2005; 52: 1655–64
   PubMed Web of Science ®Google Scholar
• Omdal R., Lunde P., Rasmussen K., Mellgren S. I., Husby G. Transesophageal and transthoracic echocardiography and Doppler‐examinations in systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 275–81
   PubMed Web of Science ®Google Scholar
• Doria A., Iaccarino L., Sarzi‐Puttini P., Atzeni F., Turriel M., Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683–6
   PubMed Web of Science ®Google Scholar
• Roldan C. A., Shively B. K., Crawford M. H. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335: 1424–30
   PubMed Web of Science ®Google Scholar
• Jensen‐Urstad K., Svenungsson E., de Faire U., Silveira A., Witztum J. L., Hamsten A., et al. Cardiac valvular abnormalities are frequent in systemic lupus erythematosus patients with manifest arterial disease. Lupus 2002; 11: 744–52
   PubMed Web of Science ®Google Scholar
• Ip W. K., Chan S. Y., Lau C. S., Lau Y. L. Association of systemic lupus erythematosus with promoter polymorphisms of the mannose‐binding lectin gene. Arthritis Rheum 1998; 41: 1663–8
   PubMed Web of Science ®Google Scholar
• Garred P., Voss A., Madsen H. O., Junker P. Association of mannose‐binding lectin gene variation with disease severity and infections in a population‐based cohort of systemic lupus erythematosus patients. Genes Immun 2001; 2: 442–50
   PubMed Web of Science ®Google Scholar
• Best L. G., Davidson M., North K. E., MacCluer J. W., Zhang Y., Lee E. T., et al. Prospective analysis of mannose‐binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation 2004; 109: 471–5
   PubMed Web of Science ®Google Scholar
• Ohlenschlaeger T., Garred P., Madsen H. O., Jacobsen S. Mannose‐binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004; 351: 260–7
   PubMed Web of Science ®Google Scholar
• Selzer F., Sutton‐Tyrrell K., Fitzgerald S., Tracy R., Kuller L., Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001; 37: 1075–82
   PubMed Web of Science ®Google Scholar
• Szalai A. J., Alarcon G. S., Calvo‐Alen J., Toloza S. M., McCrory M. A., Edberg J. C., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C‐reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 2005; 44: 864–8
   PubMed Web of Science ®Google Scholar
• Sarzi‐Puttini P., Atzeni F., Doria A., Iaccarino L., Turiel M. Tumor necrosis factor‐alpha, biologic agents and cardiovascular risk. Lupus 2005; 14: 780–4
   PubMed Web of Science ®Google Scholar
• Svenungsson E., Gunnarsson I., Fei G. Z., Lundberg I. E., Klareskog L., Frostegard J. Elevated triglycerides and low levels of high‐density lipoprotein as markers of disease activity in association with up‐regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533–40
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M. M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337–47
   PubMed Web of Science ®Google Scholar
• Pai J. K., Pischon T., Ma J., Manson J. E., Hankinson S. E., Joshipura K., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599–610
   PubMed Web of Science ®Google Scholar
• Tzoulaki I., Murray G. D., Lee A. J., Rumley A., Lowe G. D., Fowkes F. G. C‐reactive protein, interleukin‐6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976–83
   PubMed Web of Science ®Google Scholar
• Chiappelli M., Tampieri C., Tumini E., Porcellini E., Caldarera C. M., Nanni S., et al. Interleukin‐6 gene polymorphism is an age‐dependent risk factor for myocardial infarction in men. Int J Immunogenet 2005; 32: 349–53
   PubMed Web of Science ®Google Scholar
• Roman M. J., Devereux R. B., Schwartz J. E., Lockshin M. D., Paget S. A., Davis A., et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46: 194–9
   PubMed Web of Science ®Google Scholar
• Bacchetta R., Gregori S., Roncarolo M. G. CD4+ regulatory T cells: mechanisms of induction and effector function. Autoimmun Rev 2005; 4: 491–6
   PubMed Web of Science ®Google Scholar
• Pinderski Oslund L. J., Hedrick C. C., Olvera T., Hagenbaugh A., Territo M., Berliner J. A., et al. Interleukin‐10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847–53
   PubMed Web of Science ®Google Scholar
• Halvorsen B., Waehre T., Scholz H., Clausen O. P., von der Thusen J. H., Muller F., et al. Interleukin‐10 enhances the oxidized LDL‐induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res 2005; 46: 211–19
   PubMed Web of Science ®Google Scholar
• Heeschen C., Dimmeler S., Hamm C. W., Fichtlscherer S., Boersma E., Simoons M. L., , CAPTURE Study Investigators, et al. Serum level of the antiinflammatory cytokine interleukin‐10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109–14
   PubMed Web of Science ®Google Scholar
• Fei G. Z., Svenungsson E., Frostegard J., Padyukov L. The A‐1087IL‐10 allele is associated with cardiovascular disease in SLE. Atherosclerosis 2004; 177: 409–14
   PubMed Web of Science ®Google Scholar
• Koch W., Kastrati A., Bottiger C., Mehilli J., von Beckerath N., Schomig A. Interleukin‐10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001; 159: 137–44
   PubMed Web of Science ®Google Scholar
• Sholter D. E., Armstrong P. W. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505–11
   PubMed Web of Science ®Google Scholar
• Bresalier R. S., Sandler R. S., Quan H., Bolognese J. A., Oxenius B., Horgan K., , Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005; 352: 1092–102
   PubMed Web of Science ®Google Scholar
• Chan F. K., Hung L. C., Suen B. Y., Wu J. C., Lee K. C., Leung V. K., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104–10
   PubMed Web of Science ®Google Scholar
• Rossouw J. E., Anderson G. L., Prentice R. L., LaCroix A. Z., Kooperberg C., Stefanick M. L., , Writing Group for the Women's Health Initiative Investigators, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–33
   PubMed Web of Science ®Google Scholar
• Buyon J. P., Petri M. A., Kim M. Y., Kalunian K. C., Grossman J., Hahn B. H., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142: 953–62
   PubMed Web of Science ®Google Scholar
• Ettinger B., Black D. M., Mitlak B. H., Knickerbocker R. K., Nickelsen T., Genant H. K., , Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3‐year randomized clinical trial. J Am Med Assoc 1999; 282: 637–45
   PubMed Web of Science ®Google Scholar
• Barrett‐Connor E., Grady D., Sashegyi A., Anderson P. W., Cox D. A., Hoszowski K., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four‐year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 2002; 287: 847–57
   PubMed Web of Science ®Google Scholar
• Mok C. C., To C. H., Mak A., Ma K. M. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum 2005; 52: 3997–4002
   PubMed Web of Science ®Google Scholar
• Borba E. F., Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780–5
   PubMed Web of Science ®Google Scholar
• Tam L. S., Gladman D. D., Hallett D. C., Rahman P., Urowitz M. B. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142–5
   PubMed Web of Science ®Google Scholar
• Espinola R. G., Pierangeli S. S., Gharavi A. E., Harris E. N. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87: 518–22
   PubMed Web of Science ®Google Scholar
• Grundy S. M., Cleeman J. I., Merz C. N., Brewer H. B Jr., Clark L. T., Hunninghake D. B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39
   PubMed Web of Science ®Google Scholar
• Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Cook N. R., Lee I. M., Gordon D., Gaziano J. M., Manson J. E., et al. A randomized trial of low‐dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–304
   PubMed Web of Science ®Google Scholar
• Finazzi G., Marchioli R., Brancaccio V., Schinco P., Wisloff F., Musial J., et al. A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848–53
   PubMed Web of Science ®Google Scholar
• Crowther M. A., Ginsberg J. S., Julian J., Denburg J., Hirsh J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133–8
   PubMed Web of Science ®Google Scholar
• Levine S. R., Brey R. L., Tilley B. C., Thompson J. L., Sacco R. L., Sciacca R. R., et al. Antiphospholipid antibodies and subsequent thrombo‐occlusive events in patients with ischemic stroke. J Am Med Assoc 2004; 291: 576–84
   PubMed Web of Science ®Google Scholar